Thermo Fisher Scientific Inc (TMO) said on Friday it completed its 725 million euros acquisition of Belgium-based Henogen SA that will help strengthen the medical device maker's position in the fast-growing field of gene therapy manufacturing.
MORRISVILLE, N.C., Jan. 14, 2021 TrialCard Incorporated announced today it again achieved double-digit year-over-year revenue growth in 2020, despite the challenges presented by the COVID-19 pandemic. "2020 was a difficult year for everyone on many different levels," said TrialCard President and CEO Mark Bouck.
Cold chain services and supplies, surveillance equipment, printing services and biodegradable packaging among growth sectors in 2021 Thomas, the leader in product sourcing, supplier selection, and marketing solutions for industry, today released its 2020 Q4 Top Manufacturing Trends, identifying the top products and services sourced by North American manufacturers, as well as sharing predictio...
BETHESDA, Md., Jan. 14, 2021 Precision Medicine Group announced today it has acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies.
ORANGE COUNTY, Calif. Jack Jacoub, M.D., frequently sought by national news media for his expertise. "A diagnosis of cancer or certain blood disorders comes with a wide array of challenges, questions and concerns," says Dr. Jacoub's colleague Gurpreet Multani, M.D. "It affects you, your family and practically every aspect of your life.
BridgeBio Pharma, Inc. (BBIO) and Eidos Therapeutics, Inc. (EIDX) announced today that the acquisition of shares of common stock of Eidos not held by BridgeBio or its subsidiaries, on the terms and subject to the conditions of their previously announced merger agreement, is expected to close on or about January 26, 2021.
Silo Pharma, Inc. (SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinsons, and other rare neurological disorders, today announced that it has entered into a sponsored research agreement with the University of Maryland, Baltimore relating to a study to exami...
LAS VEGAS, Jan. 13, 2021 DelveInsight's 'Complement 3 Glomerulopathy Market Report 2030' report delivers an in-depth understanding of the Complement 3 Glomerulopathy, historical and forecasted C3G epidemiology, and current treatment practices.
Leading BioSciences, Inc., a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (SNCA) to form Palisade Bio, Inc., announced that the U.S. Food and Drug Administration has granted Fast Track Designation to LB1148 for the treatment of postoperative gastrointestinal dysfunction associated with pediatric heart surgery.
LOVELAND, Colo. Founded in 2016 and headquartered in Fort Collins, Colorado, Lacuna is a first-to-market digital telemedicine cytology platform that increases the standard of care veterinarians provide for pets by providing nearly real-time interpretation of cases by an expert network of board-certified clinical pathologists.
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
